New fixed dose combination in treatment of asthma: focus on mometasone furoate/formoterol



Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The review focused on mometasone furoate/formoterol (MF/F), a new fixed dose combination (Zenhale, MDI 50/5, 100/5 and 200/5 mcg/dose) for treatment of asthma in adults and children 12 years of age and older. New combination should be used for patients not adequately controlled with inhaled corticosteroids (ICS) and «as needed» inhaled short acting β 2-agonist or those whose disease severity warrants initiation of treatment with two maintenance therapies. It may be also used in patients already adequately controlled on both ICS and long-acting β 2-agonist. Data from randomized placebo controlled clinical trials confirm that MF/F has fast onset of action, reduces number of exacerbations, improves lung function, quality of life and asthma control. MF/F has a good safety profile.

Full Text

Restricted Access

About the authors

A V Emelyanov

North-Western Medical University

Email: emelav@inbox.ru
St. Petersburg, Russia

References

  1. Rabe K.F., Vermeire P.A., Soriano J.B., Maier W.C. Clinical management of asthma in 1999: the Asthma Insights and Reality in Europe (AIRE) study. Eur. Respir. J. 2000, v. 16, p. 802-807.
  2. Partridge M.R., van der Molen T, Myrseth S.E., Busse W.W. BMC. Pulm. Med. 2006, v. 6, p. 13.
  3. Емельянов А.В., Горячкина Л.А., Астафьева Н.Г. и соавт. Аллергический ринит и бронхиальная астма в реальной клинической практике: результаты Российского многоцентрового исследования. Рос. Аллергол. Журн. 2012, № 1, с. 29-33.
  4. Sharpe M., Jarvis B. Inhaled mometasonefuroate. A review of its use in adults and adolescents with persistent asthma. Drugs. 2001, v. 61, p. 1325-1350.
  5. Chapman R.W., Sehring S.L., Gallisi C.G. et al. Anti-inflammatory activity of inhaled mometasonefuroate in allergic mice. Arzneimittel Forshung. 1998, v. 48, p. 384-391.
  6. Barnes P. Optimizing the anti-inflammatory effects of corticosteroids. Eur. Respir. Rev. 2001, v. 11, p. 15-22.
  7. Bartow R.A., Brogden R.N. Formoterol. An update of its pharmacological properties and therapeutic efficacy in the management of asthma. Drugs. 1998, v. 55 (2), p. 303-322.
  8. Frampton J.E. Mometasone/Formoterol Inhalation Aerosol In Asthma Uncontrolled on Medium or High-DoseInhaled Corticosteroids. Drugs. 2012, v. 72 (9), p. 1229-1241.
  9. Nolte H., Pavord I., Backer V. et al. Dose-dependent anti-inflammatory effect of inhaled mometasonefuroate/formoterol in subjects with asthma. Respir. Med. 2013, Mar 9. pii: S0954-6111(13)00059-0 [E-pub ahead print].
  10. Berger W.E. Mometasonefuroate/formoterol in the treatment ofpersistent asthma. Expert Rev. Respir. Med. 2011, v. 5 (6), p. 739-746.
  11. Affrime M.B., Cuss F., Padhi D. et al. Bioavailability and metabolism of mometasonefuroate following administration by metered-dose and dry-powder inhalers in healthy volunteers. J. Clin. Pharm. 2000, v. 40, p. 1227-1236.
  12. Affrime M.B., Kosoglou T. The pharmacokinetics of mometasonefuroate administered by dry powder inhaler following single and multiple dosing in patients with mild and moderate persistent asthma. J. Allergy Clin. Immunol. 2001, v. 107, p. 104.
  13. Padden J., Skoner D., Hochhaus G. Pharmacokinetics and pharmacodynamics of inhaled glucocorticoids. Journal of Asthma. 2008, v. 45 (Suppl. 1), p. 13-24.
  14. Meltzer E.O., Kuna P., Nolte H. et al. Mometasonefuroate/ formoterol reduces asthma deteriorations and improves lung function. Eur. Respir. J. Epub. 2011 Aug. 4.
  15. Nathan R.A., Nolte H., Pearlman D.S. Twenty-six-week efficacy and safety study of mometasonefuroate/formoterol 200/10 mg combination treatment in patients with persistent asthma previously receiving medium-dose inhaled corticosteroids. Allergy Asthma Proc. 2010, v. 31 (4), p. 269-279.
  16. Weinstein S.F., Corren J., Murphy K. et al. Twelve-week efficacy and safety study of mometasonefuroate/formoterol 200/10 mg and 400/10 mg combination treatments in patients with persistent asthma previously receiving high-dose inhaled corticosteroids. Allergy Asthma Proc. 2010, v. 31 (4), p. 280-289.
  17. Bernstein D., Hebert J., Cheema A. et al. Efficacy and onset of action of mometasonefuroate/formoterol and fluticasone propionate/ salmeterol combination treatment in subjects with persistent asthma. Allergy, Asthma & Clinical Immunology. 2011, v. 7, p. 21.
  18. Maspero J.F., Nolte H., Cherrez-Ojeda I. et al. Long-term safety of mometasone-furoate/formoterol combination for treatment of patients with persistent asthma. J. Asthma. 2010, v. 47, p. 1106-1115.
  19. Westergaard C., Porsbjerg C., Backer V. A review of mometasonefuroate/formoterol in the treatment of asthmа. Expert Opinion on Pharmacotherapy. 2013, v. 14 (3), p. 339-346.
  20. Зенхейл. Инструкция по медицинскому применению, 2012.
  21. Weinstein C., Staudinger H., Scott I. et al. Dose counter performance of mometasonefuroate/formoterol inhalers in subjects with asthma or COPD. Respir. Med. 2011, v. 105, p. 979-988.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright © Pharmarus Print Media, 2013



This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies